Burning Rock Biotech (FRA:6BU0) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


FRA:6BU0 Burning Rock Biotech Ltd FRA:6BU0
55 GF Score
Price €6.00
GF Value €5.43
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Burning Rock Biotech's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:6BU0 vs FONR, XGN, QUCY: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Burning Rock Biotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Margin of Safety % (DCF Earnings Based) falls into.


FRA:6BU0
55GF Score
Burning Rock Biotech Ltd FRA:6BU0
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of €6.00 is trading 10.5% above its estimated GF Value™ of €5.43. GuruFocus considers Burning Rock Biotech to be Modestly Undervalued.

Key valuation signals for FRA:6BU0:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €5.43 vs. price of €6.00 (10.5% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges BNR:USA
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
55GF Score

Get the complete analysis for FRA:6BU0

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€5.43
GF Value